- Report
- May 2026
- 139 Pages
Global
From €2689EUR$2,999USD£2,306GBP
€3586EUR$3,999USD£3,075GBP
- Report
- October 2025
- 160 Pages
Global
From €2834EUR$3,160USD£2,430GBP
€3542EUR$3,950USD£3,037GBP
- Report
- October 2025
- 160 Pages
Global
From €2834EUR$3,160USD£2,430GBP
€3542EUR$3,950USD£3,037GBP
- Report
- October 2025
- 160 Pages
Global
From €2834EUR$3,160USD£2,430GBP
€3542EUR$3,950USD£3,037GBP
- Report
- October 2025
- 160 Pages
Global
From €2834EUR$3,160USD£2,430GBP
€3542EUR$3,950USD£3,037GBP
- Report
- October 2025
- 160 Pages
Global
From €2834EUR$3,160USD£2,430GBP
€3542EUR$3,950USD£3,037GBP
- Report
- November 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,729GBP
- Report
- November 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,729GBP
- Report
- November 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,729GBP
- Report
- September 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,729GBP
- Report
- August 2025
- 150 Pages
Global
From €4349EUR$4,850USD£3,729GBP
- Report
- March 2026
- 157 Pages
Global
From €3500EUR$4,181USD£3,106GBP
- Report
- September 2025
- 112 Pages
Global
From €3500EUR$4,181USD£3,106GBP
- Report
- April 2026
- 149 Pages
Global
From €4349EUR$4,850USD£3,729GBP
- Report
- April 2026
- 266 Pages
United States
From €4349EUR$4,850USD£3,729GBP
- Report
- January 2024
- 348 Pages
Global
From €5251EUR$6,060USD£4,350GBP
- Report
- January 2023
- 248 Pages
Global
From €4768EUR$5,503USD£3,950GBP
- Report
- August 2025
- 200 Pages
United States
From €2233EUR$2,490USD£1,915GBP
- Report
- May 2025
- 120 Pages
Global
From €5336EUR$5,950USD£4,575GBP
- Report
- October 2024
- 90 Pages
Global
From €5336EUR$5,950USD£4,575GBP

The Bronchodilator market is composed of inhalers and nebulisers, both of which are used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Inhalers are handheld devices that deliver medication directly to the lungs in the form of a mist or spray. Nebulisers are larger machines that convert liquid medication into a fine mist that can be inhaled. Both inhalers and nebulisers are used to deliver bronchodilators, which are medications that relax the muscles in the airways and make it easier to breathe.
Inhalers are the most commonly used form of bronchodilator delivery, as they are more convenient and cost-effective than nebulisers. Inhalers come in a variety of forms, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs). Nebulisers are typically used for more severe cases of respiratory conditions, as they can deliver a higher dose of medication than inhalers.
Some of the companies in the Bronchodilator market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. Show Less Read more